Sentien Biotechnologies
Lexington
About Sentien Biotechnologies
Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion. Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $15.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2017)
- Website: sentienbiotech.com
- Phone: 781-361-9031
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sentien-biotechnologies-119849 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.